drugset / Trial / NCT04884399
Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, two-group parallel, positive-controlled clinical Phase I trial comparing the safety, pharmacokinetics, pharmacodynamics and efficacy of CMAB818 and Lucentis® in patients with wet age-related macular degeneration.
Timeline
- Start
- 2021-06-03
- Primary completion
- 2022-12-22
- Completion
- 2022-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMAB818 | Unknown | 0.5 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |